CytoDyn, which is developing an HIV drug, has completed a capital raise of $4.3 million, according to a filing with the U.S. Securities and Exchange Commission.
The Vancouver-based biotech company finalized a private placement of 4.3 million shares of common stock and accompanying five-year warrants to purchase up to 1 million shares of common stock, at a combined price of $1, according to Seeking Alpha.
In January, CytoDyn (CYDY on the Over-The-Counter exchange) raised $33 million in equity. The…
CytoDyn, which is developing an HIV drug, has completed a capital raise of $4.3 million, according to a filing with the U.S. Securities and Exchange Commission.
The Vancouver-based biotech company finalized a private placement of 4.3 million shares of common stock and accompanying five-year warrants to purchase up to 1 million shares of common stock, at a combined price of $1, according to Seeking Alpha.
In January, CytoDyn (CYDY on the Over-The-Counter exchange) raised $33 million in equity. The…